Discovery of Novel Therapeutics Against Shiga and Ricin Toxins
Discovery of Novel Therapeutics Against Shiga and Ricin Toxins
批准号:
7641861
负责人:
DAVID B. HASLAM
金额:
$11.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
Animal ModelAntibioticsBiological AssayBiological WarfareBiologyCell Death InhibitionCellsChemicalsDiseaseDisease modelEffectivenessEscherichia coliFundingFutureGoalsHumanIn VitroIndividualInstitutesLuciferasesMediatingMissionMolecular BankMorbidity - disease rateMusPatientsPersonsPharmaceutical PreparationsPlantsPredispositionPropertyPublic HealthRicinRoleSafetyScreening procedureSecondary toShiga ToxinStructureTherapeuticTherapeutic AgentsToxic effectToxinUnited States National Institutes of Healthbaseconceptcytotoxiccytotoxicityhigh throughput screeninghuman diseasein vivoin vivo Modelinhibitor/antagonistmortalitynovel therapeuticspreventsmall molecule
中文摘要
滋贺毒素(Stx)和蓖麻毒素是由某些E.大肠杆菌菌株和植物蓖麻毒素,分别,
是人类疾病的重要原因,也是生物战的潜在因素。的治疗选择
接触这些毒素的人数有限。特别是,抗生素在蓖麻毒素暴露后没有作用
并且在暴露于产生SIX的E.杆菌同样,没有具体的
它们的失活治疗剂,也不抑制由这些毒素引起的细胞死亡。
为了确定针对Stx、蓖麻毒素和其他毒素的潜在疗法,我们先前开发了一种
毒素敏感性小分子抑制剂的基于酶的高通量筛选(HTS)。资助
通过MRCE,我们已经鉴定了几种毒素转运抑制剂。其中有化合物
其抑制蓖麻毒素和Stx对人类细胞的细胞毒性活性。在哈佛细胞研究所,
化学生物学(ICCB)和NIH分子图书馆筛选网络(MLSCN),我们正在进行
筛选大约20万种额外的化合物,以确定那些抑制毒素转运的化合物。
在上述筛选的同时,我们开发并优化了用于鉴定
直接抑制Stx和蓖麻毒素的酶活性的化合物。大约10万种化合物
将筛选它们抑制Stx和蓖麻毒素活性的能力。这些化合物将被优先考虑,
评估其作为治疗剂的潜力。这些化合物中最有前途的将是
对效价、功效和药理学性质进行结构导向的优化。最后,
将在Stx和蓖麻毒素介导的小动物模型中确定和优化有效性和毒性。
疾病抑制酶活性的化合物将是有吸引力的治疗候选物。今后
研究中,这些化合物中最有效和最耐受的将在结构上针对耐受性进行优化,
有效性和良好的体外和体内药理学性质。
该项目非常符合MRCE的使命,并对公共卫生产生重大影响。在
这些毒素如果作为生物武器被故意释放,可能会造成严重的发病率和死亡率。我们
建议鉴定和优化毒素抑制剂化合物,作为可用于预防
或治疗接触这些毒素的人。
英文摘要
Shiga toxin (Stx) and ricin, produced by certain E. coli strains and the plant Ricin communicus, respectively,
are important causes of human disease and are potential agents of biowarfare. Therapeutic options for
persons exposed to these toxins are limited. In particular, antibiotics have no role following ricin exposure
and are contraindicated in patients exposed to SIX-producing E. coli. Similarly, there are no specific
therapeutics for their inactivation, nor for inhibition of the cell death caused by these toxins.
In order to identify potential therapies against Stx, ricin, and other toxins, we previously developed a
luciferase-based high throughput screen (HTS) for small molecule inhibitors of toxin susceptibility. Funded
by the MRCE, we have thusfar identified several inhibitors of toxin transport. Among these are compounds
that inhibit the cytotoxic activity of ricin and Stx against human cells. At the Harvard Institute of Cellular and
Chemical Biology (ICCB) and the NIH Molecular Libraries Screening Network (MLSCN), we are undertaking
a screen of approximately 200,000 additional compounds to identify those that inhibit toxin transport.
In tandem with the above screen, we developed and optimized an HTS assay for the identification of
compounds that directly inhibit the enzymatic activity of Stx and ricin. Approximately 100,000 compounds
will be screened for their ability to inhibit Stx and ricin activity. These compounds will be prioritized and
evaluated for their potential as therapeutic agents. The most promising of these compounds will be
subjected to structure-guided optimization of potency, efficacy and pharmacologic properties. Finally,
efficacy and toxicity will be determined and optimized in a small animal model of Stx- and ricin-mediated
disease. Compounds that inhibit enzymatic activity will be attractive therapeutic candidates. In future
studies, the most effective and tolerated of these compounds will be structurally optimized for tolerability,
effectiveness, and favorable pharmacological properties both in vitro and in vivo.
This project fits well with the mission of the MRCE and has major implications for public health. In the
went of their intentional release as bioweapons, these toxins could significance morbidity and mortality. We
propose to identify and optimize toxin inhibitors compounds as the first drugs that could be used to prevent
or treat individuals exposed to these toxins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of MK2 kinase in toxin-associated disease
-
批准号:7945859
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2009
-
负责人:DAVID B. HASLAM
-
依托单位:
AN HTS ASSAY FOR INHIBITORS OF C. DIFFICLE TOXINS
-
批准号:8586690
-
项目类别:
-
资助金额:$3.8万
-
财政年份:2009
-
负责人:DAVID B. HASLAM
-
依托单位:
A SCREEN FOR SMALL MOLECULE INHIBITORS OF SHIGA TOXIN AND RICIN ACTIVITY
-
批准号:7850030
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2008
-
负责人:DAVID B. HASLAM
-
依托单位:
A Screen for Small Molecule Compounds that Inhibit Bacterial Toxins
-
批准号:7304738
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6696888
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:7007298
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6542592
-
项目类别:
-
资助金额:$9.56万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6843730
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
Role of ER-Localized Chaperones in Toxin Pathogenesis
-
批准号:6642011
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2002
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:6373801
-
项目类别:
-
资助金额:$11.0万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:2887701
-
项目类别:
-
资助金额:$11.65万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:6170643
-
项目类别:
-
资助金额:$10.92万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:6510811
-
项目类别:
-
资助金额:$11.02万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
GLYCOLIPIDS AND HEMOLYTIC UREMIC SYNDROME
-
批准号:2591934
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1998
-
负责人:DAVID B. HASLAM
-
依托单位:
REGULATION OF GLOBOPENTOSYLCERAMIDE EXPRESSION
-
批准号:2207194
-
项目类别:
-
资助金额:$3.5万
-
财政年份:1995
-
负责人:DAVID B. HASLAM
-
依托单位:
REGULATION OF GLOBOPENTOSYLCERAMIDE EXPRESSION
-
批准号:2207195
-
项目类别:
-
资助金额:$3.54万
-
财政年份:1995
-
负责人:DAVID B. HASLAM
-
依托单位:
海外基金